Hengrui Looks Abroad For Strategic In-Licensing Deal
This article was originally published in PharmAsia News
Jiangsu Hengrui has tested new waters to in-license its first drug candidate from overseas under an exclusive licensing agreement with Tesaro, marking its ambition to increase international collaborations under its development strategy for this year. Some analysts predict the deal may be just the start of a broader relationship.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.